Compare Pfizer Inc (PFE) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

TLH trades at $98.13, down 0.56% over 24 hours, with technical indicators signaling a bearish trend. The stock faces resistance near $99 and support at $97. Recent dividend payments of $0.41 and $0.36 in mid-2026 provide income, but key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Broader market volatility, driven by Federal Reserve uncertainty and geopolitical tensions, adds to the cautious backdrop.

The outlook for TLH remains guarded due to weak technical momentum and lack of visible fundamental strength. Investment opportunity hinges on improved earnings visibility and stabilization above key support. Risks include macroeconomic pressures and absence of current financial metrics, warranting careful monitoring for signs of operational improvement or further deterioration.